Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Xywav | 958.4 | 535.3 | 15.3 | | | | | |
| Total Oxybate | 1,978.9 | 1,801.1 | 1,757.0 | 1,642.5 | 1,404.9 | | | |
| Oncology | | | | | 425.0 | | | |
| Total Neuroscience | 2,760.9 | 2,335.4 | 1,785.4 | 1,646.2 | 1,404.9 | | | |
| Total revenues [+] | 3,659.4 | 3,094.2 | 2,363.6 | 2,161.8 | 1,890.9 | 1,618.7 | 1,488.0 | 1,324.8 |
| Products | | | | | | | | 1,316.8 |
| Revenue growth [+] | 18.3% | 30.9% | 9.3% | 14.3% | 16.8% | 8.8% | 12.3% | 13.0% |
| Xywav | 79.0% | 3406.9% | | | | | | |
| Total Oxybate | 9.9% | 2.5% | 7.0% | 16.9% | | | | |
| Total Neuroscience | 18.2% | 30.8% | 8.5% | 17.2% | | | | |
| Zepzelca | 9.4% | 173.1% | | | | | | |
| Cost of goods sold | 540.5 | 440.8 | 148.9 | 127.9 | 121.5 | 110.2 | 105.4 | 102.5 |
| Gross profit | 3,118.9 | 2,653.5 | 2,214.7 | 2,033.8 | 1,769.4 | 1,508.5 | 1,382.6 | 1,222.3 |
| Gross margin | 85.2% | 85.8% | 93.7% | 94.1% | 93.6% | 93.2% | 92.9% | 92.3% |
| Selling, general and administrative | 1,417.0 | 1,451.7 | 854.2 | 736.9 | 683.5 | 544.2 | 502.9 | 449.1 |
| Research and development | 590.5 | 505.7 | 335.4 | 299.7 | 226.6 | 198.4 | 162.3 | 135.3 |
| Equity in earnings | 9.9 | 0.7 | 3.0 | 4.1 | 2.2 | 1.0 | -0.4 | |
| Other operating expenses | | | | | | | 125.7 | 98.2 |
| EBITDA [+] | 1,151.7 | 723.5 | 1,046.7 | 1,016.6 | 876.7 | 780.0 | 705.1 | 647.8 |
| EBITDA growth | 59.2% | -30.9% | 3.0% | 16.0% | 12.4% | 10.6% | 8.8% | 75.7% |
| EBITDA margin | 31.5% | 23.4% | 44.3% | 47.0% | 46.4% | 48.2% | 47.4% | 48.9% |
| Depreciation | 30.3 | 26.7 | 18.7 | 15.3 | 15.2 | 13.1 | 11.8 | 9.9 |
| EBITA | 1,121.4 | 696.8 | 1,028.0 | 1,001.3 | 861.4 | 766.9 | 693.3 | 637.9 |
| EBITA margin | 30.6% | 22.5% | 43.5% | 46.3% | 45.6% | 47.4% | 46.6% | 48.2% |
| Amortization of intangibles | 599.2 | 525.8 | 259.6 | 354.8 | 201.5 | 152.1 | 102.0 | 98.2 |
| EBIT [+] | 522.2 | 171.0 | 768.4 | 646.4 | 659.9 | 614.9 | 591.3 | 539.7 |
| EBIT growth | 205.4% | -77.7% | 18.9% | -2.0% | 7.3% | 4.0% | 9.5% | 129.7% |
| EBIT margin | 14.3% | 5.5% | 32.5% | 29.9% | 34.9% | 38.0% | 39.7% | 40.7% |
| Non-recurring items [+] | 577.8 | | 387.4 | 110.0 | 42.9 | 85.0 | | 31.5 |
| Asset impairment | 133.6 | | 136.1 | | 42.9 | | | 31.5 |
| In-process research & development | 444.1 | | 251.3 | 110.0 | | 85.0 | | |
| Interest expense, net [+] | -299.7 | -280.6 | -110.8 | -92.8 | -95.4 | -81.9 | 61.9 | 56.9 |
| Interest expense | -288.2 | -278.8 | -99.7 | -72.3 | -78.5 | -77.8 | 61.9 | 56.9 |
| Interest income | 11.5 | 1.8 | 11.1 | 20.5 | 16.9 | 4.1 | | |
| Other income (expense), net [+] | -616.9 | -564.4 | -216.7 | -174.9 | -183.0 | -170.6 | 3.1 | -15.4 |
| Gain (loss) on foreign currency transactions | -19.0 | -4.4 | -3.3 | -5.8 | -6.9 | -10.0 | 3.4 | 1.4 |
| Pre-tax income | -372.8 | -112.8 | 275.1 | 454.3 | 529.5 | 441.1 | 532.4 | 435.9 |
| Income taxes | -158.6 | 216.1 | 33.5 | -73.2 | 80.2 | -47.7 | 135.2 | 106.4 |
| Tax rate | 42.6% | | 12.2% | | 15.1% | | 25.4% | 24.4% |
| Minority interest | | | | | | | | 0.0 |
| Net income | -224.1 | -329.7 | 238.6 | 523.4 | 447.1 | 487.8 | 396.8 | 329.5 |
| Net margin | -6.1% | -10.7% | 10.1% | 24.2% | 23.6% | 30.1% | 26.7% | 24.9% |
| |
| Basic EPS [+] | ($3.58) | ($5.52) | $4.28 | $9.22 | $7.45 | $8.13 | $6.56 | $5.38 |
| Growth | -35.1% | -228.9% | -53.6% | 23.7% | -8.3% | 23.9% | 21.9% | 450.7% |
| Diluted EPS [+] | ($3.58) | ($5.52) | $4.22 | $9.09 | $7.30 | $7.96 | $6.41 | $5.23 |
| Growth | -35.1% | -230.8% | -53.6% | 24.5% | -8.2% | 24.0% | 22.7% | 460.6% |
| |
| Shares outstanding (basic) [+] | 62.5 | 59.7 | 55.7 | 56.7 | 60.0 | 60.0 | 60.5 | 61.2 |
| Growth | 4.8% | 7.1% | -1.8% | -5.4% | -0.1% | -0.8% | -1.2% | 2.5% |
| Shares outstanding (diluted) [+] | 62.5 | 59.7 | 56.5 | 57.6 | 61.2 | 61.3 | 61.9 | 63.0 |
| Growth | 4.8% | 5.6% | -1.8% | -6.0% | -0.2% | -0.9% | -1.8% | 0.7% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|